Estrogen-Only Therapy Linked to Lower Breast Cancer Risk Post-Hysterectomy

A meta-analysis of 10 randomized trials involving 14,282 participants at population risk found that estrogen-only therapy was associated with a lower breast cancer diagnosis rate than placebo (3.6% vs 4.7%; relative risk 0.77; 95% CI, 0.65-0.91, P=.002). A separate matched prospective cohort study of 676 patients with BRCA mutations and intact breasts reported a 15-year cumulative breast cancer incidence of 24.3% among estrogen-alone users versus 47.3% among nonusers of menopausal hormone therapy (P<.0001). The source notes that more data specifically evaluating estradiol therapy in patients who have undergone hysterectomy are needed.

Most relevant for: Patients who have undergone or are planning hysterectomy for benign gynecologic conditions, including those with BRCA pathogenic variants, who are considering menopausal hormone therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.